College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Department of Community Health Sciences, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
PLoS One. 2022 Dec 1;17(12):e0278470. doi: 10.1371/journal.pone.0278470. eCollection 2022.
The overall impact of physician prescribers on population-level adherence rates are unknown. We aimed to quantify the influence of general practitioner (GP) physician prescribers on the outcome of optimal statin medication adherence.
We conducted a retrospective cohort study using health administrative databases from Saskatchewan, Canada. Participants included physician prescribers and their patients beginning a new statin medication between January 1, 2012 and December 31, 2017. We grouped prescribers based on the prevalence of optimal adherence (i.e., proportion of days covered ≥ 80%) within their patient group. Also, we constructed multivariable logistic regression analyses on optimal statin adherence using two-level non-linear mixed-effects models containing patient and prescriber-level characteristics. An intraclass correlation coefficient was used to estimate the physician effect.
We identified 1,562 GPs prescribing to 51,874 new statin users. The median percentage of optimal statin adherence across GPs was 52.4% (inter-quartile range: 35.7% to 65.5%). GP prescribers with the highest patient adherence (versus the lowest) had patients who were older (median age 61.0 vs 55.0, p<0.0001) and sicker (prior hospitalization 39.4% vs 16.4%, p<0.001). After accounting for patient-level factors, only 6.4% of the observed variance in optimal adherence between patients could be attributed to GP prescribers (p<0.001). The majority of GP prescriber influence (5.2% out of 6.4%) was attributed to the variance unexplained by patient and prescriber variables.
The overall impact of GP prescribers on statin adherence appears to be very limited. Even "high-performing" physicians face significant levels of sub-optimal adherence among their patients.
医生开处方对人群水平的遵医嘱率的整体影响尚不清楚。我们旨在量化全科医生(GP)开处方者对最佳他汀类药物依从性结果的影响。
我们使用来自加拿大萨斯喀彻温省的健康管理数据库进行了回顾性队列研究。参与者包括 2012 年 1 月 1 日至 2017 年 12 月 31 日期间开始使用新他汀类药物的开处方者及其患者。我们根据患者群体中最佳依从性(即覆盖率≥80%的天数比例)的流行程度对开处方者进行分组。此外,我们使用包含患者和开处方者特征的两水平非线性混合效应模型对最佳他汀类药物依从性进行多变量逻辑回归分析。使用组内相关系数估计医生的影响。
我们确定了 1562 名向 51874 名新他汀类药物使用者开处方的全科医生。GP 开处方者的最佳他汀类药物依从率中位数为 52.4%(四分位距:35.7%至 65.5%)。与依从性最低的患者相比,依从性最高的患者年龄更大(中位数 61.0 岁 vs 55.0 岁,p<0.0001)且病情更重(既往住院率 39.4% vs 16.4%,p<0.001)。在考虑了患者水平因素后,患者之间最佳依从性的观察到的差异只有 6.4%可以归因于 GP 开处方者(p<0.001)。GP 开处方者的大部分影响(6.4%中的 5.2%)归因于无法用患者和开处方者变量解释的方差。
GP 开处方者对他汀类药物依从性的总体影响似乎非常有限。即使是“表现良好”的医生,其患者的依从性也存在显著的不理想水平。